PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS study

•Heterozygous familial hypercholesterolemia is underdiagnosed in children, placing them at risk of cardiovascular events.•Target low-density lipoprotein cholesterol levels are often not reached despite optimal lipid-modifying therapies.•We assessed the effects, safety, and doses of alirocumab in pediatric patients with heterozygous familial hypercholesterolemia.•Reductions in low-density lipoprotein cholesterol were observed across all assessed doses.•Overall, treatment with alirocumab was generally well tolerated.